Free shipping on orders over €75 within the EU.
Discounted shipping on orders over €75 outside the EU.
VIRALEZE™ was developed in Australia by Starpharma
Starpharma is a world leader in dendrimer technology and is listed on the Australian Securities Exchange (ASX code: SPL) headquartered in Melbourne, Australia.
Starpharma is a world leader in the development of new medical products based on its proprietary dendrimer technology and has partnerships with leading global pharmaceutical companies, including AstraZeneca, MSD (Merck & Co., Inc.,), Okamoto, Aspen and Mundipharma. Starpharma is listed on the Australian stock exchange (ASX:SPL)
Image: Dendrimer image of astodrimer sodium (SPL7013)
Starpharma developed VIRALEZE™, an easy-to-use antiviral nasal spray.
VIRALEZE™ contains astodrimer sodium, which has been shown in laboratory studies to inactivate viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Starpharma was awarded development funding for VIRALEZE™ by the Australian Government’s Medical Research Future Fund Biomedical Translation Bridge Program. VIRALEZE™ is registered for sale in the UK/Europe, India, Vietnam and Saudi Arabia.
Astodrimer sodium (SPL7013) in VIRALEZE™ is also included in approved products – the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Southeast Asia, South Africa, Australia, and New Zealand.